Form 4: Natera Co-Founder Jonathan Sheena Sells Shares

Natera, Inc. Co-Founder Jonathan Sheena sold 3,150 shares of common stock via a pre-arranged Rule 10b5-1 trading plan.

Summary

• Jonathan Sheena, Co-Founder of Natera, Inc., executed the sale of 3,150 shares of common stock on June 15, 2026.
• The shares were sold in four separate tranches at weighted average prices ranging from $210.29 to $213.54 per share.
• The transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2025.
• Following these transactions, Sheena retains direct ownership of 249,352 shares of Natera common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event; the sale is a routine, pre-planned divestment by a co-founder and does not reflect a change in company fundamentals.

Positives

• The sale was conducted under a pre-established Rule 10b5-1 trading plan, which is a standard mechanism for insiders to sell stock without triggering concerns regarding non-public information.

Negatives

• Insider selling can sometimes be perceived by the market as a signal that the stock is fully valued or that the insider is taking profits.

Risks

• Continued reliance on Rule 10b5-1 plans for liquidity by key insiders.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing, as it is a standard disclosure of insider transaction activity.

Industry Context

StockSavvy.ai notes that insider selling via 10b5-1 plans is a routine corporate governance practice in the biotechnology and diagnostics sector, often used by founders to manage personal liquidity while maintaining significant long-term equity stakes.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for executives at companies like Exact Sciences or Guardant Health to ensure compliance with SEC regulations during stock divestment.

Related Party Transactions

• The reporting person maintains indirect interest in 19,532 shares held by Caraluna 1 Trust and 19,532 shares held by Caraluna 2 Trust.

Stakeholder Impact

• Minimal impact on shareholders as the sale was pre-planned and represents a small fraction of the total outstanding shares.

Next Steps

• Continued monitoring of future Form 4 filings for further insider activity.

Key Dates

Keywords

Natera, NTRA, Insider Trading, Form 4, Jonathan Sheena, Equity Sale